TABLE 2.

Minimum bactericidal concentration (MBC) (μg/mL)^¶ and MBC/MIC ratio of benzohydrazides and phenylacetamide derivatives (1–29) against a panel of organisms.

Compound	E. Coli		MRSA		MRSA
	(NCIM 2065)a		(NCIM 5021)b		(ATCC43300)c
	MBC	MBC/MIC	MBC	MBC/MIC	MBC	MBC/MIC
1	1.42 ± 0.02	2	0.84 ± 0.13	1	0.99 ± 0.24	1
2	2.00 ± 0.01	2	4.8 ± 0.21	2	2.71 ± 0.21	2
3	1.75 ± 0.09	1	1.84 ± 0.13	1	1.79 ± 0.21	1
4	4.71 ± 0.03	2	8.00 ± 0.04	3	8.76 ± 0.21	3
5	0.64 ± 0.42	1	1.54 ± 0.11	2	0.68 ± 0.08	1
6	3.7 ± 0.12	3	7.39 ± 0.18	4	4.56 ± 0.08	3
7	0.83 ± 0.1	1	0.95 ± 0.06	1	0.85 ± 0.09	1
8	0.93 ± 0.03	1	0.63 ± 0.13	1	2.46 ± 0.12	2
9	3.68 ± 0.29	2	4.70 ± 0.41	3	6.29 ± 0.08	4
10	0.83 ± 0.05	1	0.82 ± 0.03	1	0.88 ± 0.10	1
11	0.97 ± 0.01	1	7.18 ± 0.15	4	0.84 ± 0.05	1
12	0.86 ± 0.03	1	4.4 ± 0.15	2	0.96 ± 0.14	1
13	9.43 ± 0.11	4	–	–	–	–
14	0.98 ± 0.07	1	–	–	0.94 ± 0.14	1
15	–	–	–	–	3.18 ± 0.32	2
16	9.12 ± 0.11	4	–	–	–	–
17	7.2 ± 0.7	2	7.46 ± 0.05	2	–	–
18	1.42 ± 0.23	1	1.81 ± 0.40	1	3.74 ± 0.16	2
19	2.06 ± 0.14	1	5.37 ± 0.11	2	4.74 ± 0.16	2
20	4.59 ± 0.26	1	–	–	–	–
21	0.67 ± 0.02	1	0.68 ± 0.005	1	2.16 ± 0.30	3
22	0.89 ± 0.01	1	0.90 ± 0.04	1	0.76 ± 0.06	1
23	0.95 ± 0.05	1	0.94 ± 0.04	1	0.75 ± 0.11	1
24	0.78 ± 0.08	1	0.81 ± 0.10	1	0.73 ± 0.12	1
25	7.09 ± 0.02	3	8.37 ± 0.17	3	–	–
26	0.72 ± 0.05	1	0.86 ± 0.13	1	4.32 ± 0.10	4
27	1.59 ± 0.38	1	3.55 ± 0.07	2	1.06 ± 0.14	1
28	3.85 ± 0.25	2	10.62 ± 0.44	4	–	–
29	0.81 ± 0.14	1	0.75 ± 0.19	1	0.91 ± 0.11	1
Cipro	1.42 ± 0.02	2	0.84 ± 0.13	1	0.99 ± 0.24	1

^¶ Values are mean ± SEM (n = 3).

“–”: not determined; Positive control = Ciprofloxacin.

^aE. coli, Escherichia Coli (NCIM 2065).

^bMRSA, Methicillin resistant Staphylococcus aureus (NCIM 5021).

^cMRSA, Methicillin resistant Staphylococcus aureus (ATCC 43300).